S309 chimeric antigen receptors and methods of use
AssigneeRutgers, The State University of New Jersey
InventorsDongfang Liu, Minh Ma, Saiaditya Badeti
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors (CARs) including an scFv binding to coronavirus spike protein (S309 scFv), nucleic acids encoding the CARs, vectors including nucleic acids encoding the CARs, and cells expressing the CARs are provided. Methods of treating a subject with coronavirus are also provided, including administering to the subject a modified immune cell expressing a disclosed CAR.
Claims16
A method of treating a subject having or suspected of having a coronavirus infection, comprising administering to the subject an effective amount of a modified immune cell comprising a chimeric antigen receptor comprising at least 93% sequence identity to the amino acid sequence of SEQ ID NO:
- 1, wherein the chimeric antigen receptor comprises an antigen binding domain comprising the variable heavy chain (VH) domain complementarity determining region 1 (CDR1), CDR2 and CDR3 amino acid sequences of amino acid positions 47-54, 72-79, and 118-137 of SEQ ID NO:
- 1, respectively, and the variable light chain (VL) domain CDR1, CDR2 and CDR3 amino acid sequences of amino acid positions 195-201, 219-221, and 258-265 of SEQ ID NO:
- 1, respectively.
A method of treating a subject having or suspected of having a coronavirus infection, comprising administering to the subject an effective amount of a composition comprising:
- (i) a modified immune cell comprising a chimeric antigen receptor comprising at least 93% sequence identity to the amino acid sequence of SEQ ID NO:
- 1, wherein the chimeric antigen receptor comprises an antigen binding domain comprising the variable heavy chain (VH) domain complementarity determining region 1 (CDR1), CDR2 and CDR3 amino acid sequences of amino acid positions 47-54, 72-79, and 118-137 of SEQ ID NO:
- 1, respectively, and the variable light chain (VL) domain CDR1, CDR2 and CDR3 amino acid sequences of amino acid positions 195-201, 219-221, and 258-265 of SEQ ID NO:
- 1, respectively;
- and (ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.